EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

SARS-CoV-2 Antibody Response and Sustainability after a Third Dose of BNT162b2 in Healthcare Workers at Health Promotion Centers

Eun-Hee Nah iD, Seon Cho, Hyeran Park, Suyoung Kim, Dongwon Noh, Eunjoo Kwon, Han-Ik Cho

Viruses · 2023

DOI: 10.3390/v15030751 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Viruses, 2023. Verfasst von Eun-Hee Nah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Health Promotion Research Institute, Korea Association of Health Promotion, Seoul 07572, Republic of Korea. Hauptthemen laut MEDLINE: BNT162 Vaccine, COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to determine the antibody response and the sustainability of immunogenicity after a third dose of BNT162b2 (BNT) in homologous [ChAdOx1 (ChAd)/ChAd, BNT/BNT, and mRNA-1273 (Moderna)/Moderna] and heterologous (ChAd/BNT) vaccinations of two primary doses with different schemes. This prospective observational study recruited consenting healthcare workers from 16 health checkup centers in 13 Korean cities. Three-point blood tests were analyzed as the antibody response after the third vaccination: T3-1 (1 month after the third dose), T3-3 (3 months after the third dose), and T3-4–10 (4–10 months after the third dose). SARS-CoV-2 antibodies were measured using a chemiluminescence microparticle immunoassay with SARS-CoV-2 IgG II Quant in the ARCHITECT system (Abbott Diagnostics). The antibody levels were significantly higher in the Moderna /Moderna and BNT/BNT groups than in the ChAd/ ChAd and ChAd/BNT groups (p < 0.05) at T3-1. At T3-3, antibody levels had decreased by 29.1% in the BNT/BNT group and by 45.3% in the ChAd/ChAd group compared with the antibody levels at T3-1. The anti-SARS-CoV-2 S-RBD IgG levels at T3-1 were significantly associated with having received mRNA vaccines as the two primary doses (p < 0.001). The third dose of BNT induced an increased humoral immune response in various vaccination schemes, which was more prominent for the two primary doses of homologous mRNA vaccines. However, this immunogenicity decreased within 3–10 months after the third dose. These results suggest that another booster dose (a fourth dose), which would be able to counteract SARS-CoV-2 variants, is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BNT162 VaccineCOVID-19HumansAntibody FormationSARS-CoV-2mRNA VaccinesAntibodies, ViralHealth PersonnelHealth PromotionImmunoglobulin GVaccination

Stichwörter der Autor:innen

SARS-CoV-2anti-spike-protein receptor-binding domain (S-RBD) antibodiesmRNA vaccinesthird dosevaccination

Substanzen

BNT162 VaccinemRNA VaccinesAntibodies, ViralImmunoglobulin G

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Health Promotion Research Institute, Korea Association of Health Promotion, Seoul 07572, Republic of Korea.
  • MEDIcheck LAB, Korea Association of Health Promotion, Seoul 07572, Republic of Korea.

ORCID-Profile: Eun-Hee Nah

Zitieren

APA

Nah, E. H., Cho, S., Park, H., Kim, S., Noh, D., Kwon, E., & Cho, H. I. (2023). SARS-CoV-2 Antibody Response and Sustainability after a Third Dose of BNT162b2 in Healthcare Workers at Health Promotion Centers. Viruses. https://doi.org/10.3390/v15030751

Vancouver

Nah EH, Cho S, Park H, Kim S, Noh D, Kwon E, et al. SARS-CoV-2 Antibody Response and Sustainability after a Third Dose of BNT162b2 in Healthcare Workers at Health Promotion Centers. Viruses. 2023. doi:10.3390/v15030751

BibTeX
@article{Nah2023,
  author = {Nah, Eun-Hee and Cho, Seon and Park, Hyeran and Kim, Suyoung and Noh, Dongwon and Kwon, Eunjoo and Cho, Han-Ik},
  title = {SARS-CoV-2 Antibody Response and Sustainability after a Third Dose of BNT162b2 in Healthcare Workers at Health Promotion Centers},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15030751}
}
Kostenlos starten →